Literature DB >> 25231629

Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study.

Gregory L Sahlem1, Benjamin Kalivas2, James B Fox3, Kayla Lamb3, Amanda Roper3, Emily N Williams3, Nolan R Williams4, Jeffrey E Korte5, Zachary D Zuschlag3, Salim El Sabbagh3, Constance Guille3, Kelly S Barth2, Thomas W Uhde3, Mark S George4, E Baron Short2.   

Abstract

Previous studies have demonstrated that combined total sleep deprivation (Wake therapy), sleep phase advance, and bright light therapy (Triple Chronotherapy) produce a rapid and sustained antidepressant effect in acutely depressed individuals. To date no studies have explored the impact of the intervention on unipolar depressed individuals with acute concurrent suicidality. Participants were suicidal inpatients (N = 10, Mean age = 44 ± 16.4 SD, 6F) with unipolar depression. In addition to standard of care, they received open label Triple Chronotherapy. Participants underwent one night of total sleep deprivation (33-36 h), followed by a three-night sleep phase advance along with four 30-min sessions of bright light therapy (10,000 lux) each morning. Primary outcome measures included the 17 item Hamilton depression scale (HAM17), and the Columbia Suicide Severity Rating Scale (CSSRS), which were recorded at baseline prior to total sleep deprivation, and at protocol completion on day five. Both HAM17, and CSSRS scores were greatly reduced at the conclusion of the protocol. HAM17 scores dropped from a mean of 24.7 ± 4.2 SD at baseline to a mean of 9.4 ± 7.3 SD on day five (p = .002) with six of the ten individuals meeting criteria for remission. CSSRS scores dropped from a mean of 19.5 ± 8.5 SD at baseline to a mean of 7.2 ± 5.5 SD on day five (p = .01). The results of this small pilot trial demonstrate that adjunctive Triple Chronotherapy is feasible and tolerable in acutely suicidal and depressed inpatients. Limitations include a small number of participants, an open label design, and the lack of a comparison group. Randomized controlled studies are needed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronotherapy; Depression; Inpatients; Phototherapy; Sleep deprivation; Suicidal ideation

Mesh:

Year:  2014        PMID: 25231629      PMCID: PMC4252537          DOI: 10.1016/j.jpsychires.2014.08.015

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  37 in total

1.  A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms.

Authors:  J A Horne; O Ostberg
Journal:  Int J Chronobiol       Date:  1976

Review 2.  The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis.

Authors:  J C Wu; W E Bunney
Journal:  Am J Psychiatry       Date:  1990-01       Impact factor: 18.112

3.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

4.  The cognitive effects of electroconvulsive therapy in community settings.

Authors:  Harold A Sackeim; Joan Prudic; Rice Fuller; John Keilp; Philip W Lavori; Mark Olfson
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

5.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

7.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

8.  Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression.

Authors:  Francesco Benedetti; Roberta Riccaboni; Clara Locatelli; Sara Poletti; Sara Dallaspezia; Cristina Colombo
Journal:  J Clin Psychiatry       Date:  2014-02       Impact factor: 4.384

Review 9.  Chronotherapeutics in a psychiatric ward.

Authors:  Francesco Benedetti; Barbara Barbini; Cristina Colombo; Enrico Smeraldi
Journal:  Sleep Med Rev       Date:  2007-08-03       Impact factor: 11.609

Review 10.  Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy.

Authors:  Caroline Caddy; Giovanni Giaroli; Thomas P White; Sukhwinder S Shergill; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-04
View more
  12 in total

Review 1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

Authors:  Arun V Ravindran; Lynda G Balneaves; Guy Faulkner; Abigail Ortiz; Diane McIntosh; Rachel L Morehouse; Lakshmi Ravindran; Lakshmi N Yatham; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

2.  Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.

Authors:  Wallace C Duncan; Elizabeth D Ballard; Carlos A Zarate
Journal:  Handb Exp Pharmacol       Date:  2019

3.  Diurnal Variation of the Peripheral Cholinergic Antiinflammatory Function in Mice.

Authors:  Bo-Shi Fan; En-Hui Zhang; Ming-He Cheng; Zhao-Tang Wu; Bing Han; Jian-Guang Yu
Journal:  CNS Neurosci Ther       Date:  2016-06-16       Impact factor: 5.243

4.  Correcting delayed circadian phase with bright light therapy predicts improvement in ADHD symptoms: A pilot study.

Authors:  Rachel E Fargason; Aaron D Fobian; Lauren M Hablitz; Jodi R Paul; Brittny A White; Karen L Cropsey; Karen L Gamble
Journal:  J Psychiatr Res       Date:  2017-03-06       Impact factor: 4.791

5.  Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder.

Authors:  Elizabeth D Ballard; Jennifer L Vande Voort; Rebecca A Bernert; David A Luckenbaugh; Erica M Richards; Mark J Niciu; Maura L Furey; Wallace C Duncan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384

Review 6.  Suicidality in sleep disorders: prevalence, impact, and management strategies.

Authors:  Christopher W Drapeau; Michael R Nadorff
Journal:  Nat Sci Sleep       Date:  2017-09-14

7.  Effects of Different Spectral Energy Distributions on Physiological Behavior and Hormone Levels in Depression.

Authors:  Chunyu Yang; Zhiyuan Zhang; Juntao Ma; Ting Chen
Journal:  Iran J Public Health       Date:  2018-03       Impact factor: 1.429

8.  Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine.

Authors:  Elizabeth D Ballard; Jessica Fields; Cristan A Farmer; Carlos A Zarate
Journal:  Suicide Life Threat Behav       Date:  2021-02

Review 9.  Role of Chronobiology as a Transdisciplinary Field of Research: Its Applications in Treating Mood Disorders.

Authors:  Okan Çalıyurt
Journal:  Balkan Med J       Date:  2017-10-26       Impact factor: 2.021

Review 10.  The effect of chronotherapy on depressive symptoms. Evidence-based practice.

Authors:  Anas H Khalifeh
Journal:  Saudi Med J       Date:  2017-05       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.